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Background. Recent studies have demonstrated that a high
concentration of phosphate directly stimulates parathyroid hor-
mone (PTH) secretion. High serum levels of phosphate are
usually observed in patients with end-stage renal disease. The aim
of the present study was to evaluate whether serum phosphate
concentration had an acute effect on PTH secretion in hemodi-
alysis patients. The levels of serum phosphate were manipulated
during the hemodialysis session by using a phosphate free dialy-
sate or a dialysate with a high content of phosphate.
Methods. Ten stable hemodialysis patients with PTH values
above 300 pg/ml were included in the study. A PTH-calcium curve
was obtained during both high phosphate and phosphate free
hemodialysis.
Results. The serum phosphate concentration remained high
(2.17 6 0.18 mM) throughout the high phosphate hemodialysis
and decreased progressively to normal levels (1.02 6 0.06 mM)
during the phosphate free hemodialysis. The serum PTH levels at
maximal inhibition by hypercalcemia (minimal PTH) were greater
during the high phosphate than the phosphate free hemodialysis
(413 6 79 vs. 318 6 76 pg/ml, P , 0.003). In all patients the values
of minimum PTH were greater during the high phosphorus than
the phosphorus free hemodialysis. The values of maximally stim-
ulated PTH during hypocalcemia and the set point of the PTH-
calcium curve were similar during the high phosphate and the
phosphate free hemodialysis.
Conclusion. The maintenance of high serum phosphorus levels
during hemodialysis prevented, in part, the inhibition of PTH
secretion by calcium, which strongly suggests that in hemodialysis
patients high serum phosphate contributes directly to the eleva-
tion of PTH levels despite normal or high serum calcium concen-
tration.
Hyperparathyroidism is a common finding in patients
with renal insufficiency. Calcitriol deficiency and phosphate
retention together with hypocalcemia are the main factors
involved in the pathogenesis of secondary hyperparathy-
roidism [1]. Phosphate retention is considered to be a key
pathogenic factor because it decreases calcitriol production
and interferes with the calcemic effect of PTH [2–5]. In
addition, recent work demonstrates that high extracellular
phosphate directly stimulates PTH secretion and gene
transcription independently of the calcitriol and calcium
levels [6]. The importance of phosphate retention as a
cause of secondary hyperparathyroidism is illustrated by
the fact that in animals and humans with renal insufficiency,
dietary phosphorus restriction prevents the development of
secondary hyperparathyroidism [7–12]. Furthermore, in
dialysis patients in whom secondary parathyroid hyperpla-
sia is already established, calcitriol administration fails to
decrease PTH levels when the serum phosphate concentra-
tion is not controlled [13].
Almaden et al showed that, in vitro, a high extracellular
phosphate concentration prevented the inhibition of PTH
secretion by a high calcium concentration in the incubation
medium [14]. Other authors have obtained similar results
in in vitro experiments [15, 16]. Whether these findings are
reproducible in vivo in uremic patients is unknown. This is
an important question to be addressed since situations of
high serum phosphate concentrations associated with hy-
perparathyroidism are usually present in end-stage renal
disease patients.
During hemodialysis, there is a decrease in serum PTH
levels caused by the influx of calcium from the dialysate to
the blood. At the same time, during the first one to two
hours of hemodialysis there is a decrease in serum phos-
phate that potentially could directly affect PTH secretion.
The aim of the present study was to investigate the effect of
changes in serum phosphate concentration on the dynamics
of calcium regulated PTH secretion (PTH-calcium curve).
To accomplish this goal, the PTH-calcium curve was deter-
mined in uremic patients during hemodialysis with and
without a concomitant decrease in serum phosphate. Se-
rum phosphate was changed by manipulating the concen-
tration of phosphate in the dialysate.
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METHODS
The study was performed in 10 stable hemodialysis
patients: seven females and three males. The mean age
(mean 6 SE) was 62.7 6 12 years (range 37 to 81 years), and
their average length of time on dialysis was 52 months
(range 5 to 120 months). All patients had serum PTH levels
greater than 300 pg/ml. The serum aluminum levels were
less than 50 mg/liter in nine patients and 86 mg/liter in one.
Vitamin D treatment was discontinued two months before
the study. Diabetic patients were excluded. To control
serum phosphate, the patients received calcium carbonate
or calcium acetate. Patients were on a four-hour three
times per week hemodialysis schedule. The research pro-
tocol and the consent form was approved by the Hospital
Ethics Committee; each patient was informed about the
study and a signed consent form was obtained before
entering the study.
In eight patients, the PTH-calcium curve was obtained
twice: during the conventional hemodialysis using the phos-
phate-free dialysate (P-free) and during hemodialysis using
a dialysate containing high phosphate (high-P). Thus, each
patient was dialyzed in four consecutive hemodialysis ses-
sions using the following dialysate concentrations: (a) low
calcium (1.5 mEq/liter), high-P (1.9 to 2.6 mM); (b) low
calcium (1.5 mEq/liter), P-free; (c) high calcium (3.5 mEq/
liter), high-P (1.9 to 2.6 mM); and (d) high calcium (3.5
mEq/liter), P-free. The high phosphate dialysate was ob-
tained by adding sodium phosphate buffer to attain the
desired dialysate phosphate concentration, which was be-
tween 1.9 and 2.6 mM (values measured after dilution). Two
additional patients underwent the two high calcium hemo-
dialyses and the low calcium hemodialysis was not per-
formed. Patients underwent the two low Ca hemodialysis
first (the high-P and P-free) and three weeks later the other
two high Ca hemodialysis sessions. The time period allowed
between the two high or low Ca hemodialysis sessions was
one week. In four patients, the P-free hemodialysis was
performed first in both high and low calcium hemodialysis
regimens; in the other six patients the order was reversed.
The magnesium concentration in the dialysate was 1 mEq/
liter.
Serum ionized calcium, phosphate, magnesium and in-
tact PTH were determined every 30 minutes throughout
the 240 minutes of the hemodialysis study. After comple-
tion of the high-P dialysis, the patients were immediately
changed to a phosphate free dialysate for one additional
hour. Using this maneuver, the patients completed the
hemodialysis session with a phosphate level below 1.45 mM.
To avoid PTH adsorption to hydrophobic membranes,
cuprophan membranes were used in all cases [17].
From the data obtained during hemodialysis-induced
hypocalcemia and hypercalcemia, two individual PTH-
calcium curves, with and without phosphate in the dialy-
sate, were constructed for each patient. For analysis of the
PTH-Ca curves the following terms were defined [18]: (1)
basal PTH was the predialysis PTH level; (2) maximal PTH
was the highest PTH level observed in response to hypocal-
cemia with no further increase of PTH produced by an
additional reduction of serum calcium. (3) Minimal PTH
was the lowest PTH level during suppression by hypercal-
cemia with no further decrease of PTH produced by an
additional increase of serum calcium. (4) The ratio of basal
to maximal PTH was the basal PTH divided by the maximal
PTH, and this fraction was multiplied by 100 to provide a
percentage. This ratio should indicate the relative degree of
PTH stimulation in the basal state, and in normal volun-
teers this ratio is 20 to 25% [19]. (5) The set point of
calcium was defined as we have done in prior studies [13,
18, 20], as the serum calcium concentration at which
maximal PTH secretion was reduced by 50%. (6) Basal
serum calcium was the serum calcium concentration at the
basal (predialysis) PTH. (7) The serum calcium at maximal
PTH (Camax) was the serum calcium concentration at which
the PTH level was first observed to be maximal or within
10% of the maximal PTH. This definition was used because
the PTH-calcium curve is sigmoidal, and as the PTH value
approaches the asymptotic portion of the curve a consid-
erable variation in serum calcium can be observed during
small changes in PTH. For the same reason, (8) the serum
calcium at minimal PTH (Camin) was defined as the serum
calcium concentration at which the PTH level was first
observed to be minimal or within 10% of the minimal PTH.
Intact PTH was measured with an immunoradiometric
assay for parathyroid hormone (Allegro; Nichols Institute,
San Juan Capistrano, CA, USA). Normal values are 10 to
65 pg/ml and the range of the standard curve is 0 to 1400
pg/ml. During the low and high calcium studies, serum
ionized calcium was measured at the bedside with a selec-
tive ionized calcium electrode (Ciba-Corning SA, Madrid,
Spain); the normal range for ionized calcium using this
method is 1.19 to 1.28. The serum phosphate, alkaline
phosphatase, albumin and bicarbonate were measured by
standard laboratory techniques.
Statistical analysis
The nonparametric Wilcoxon test was used to compare
paired data. Differences between more than two means
were evaluated by analysis of variance for repeated mea-
sures. The data are expressed as the mean 6 SE.
RESULTS
Biochemical and demographical data for the patients
included in the study are presented in Table 1.
Changes in serum phosphate concentration during the
P-free and high-P hemodialyses are shown in Figure 1.
During the regular, P-free hemodialysis, the serum phos-
phate decreased progressively from 2.93 6 0.23 to 1.02 6
0.06 mM (P , 0.001). At 90 minutes, the serum phosphate
concentration was 1.23 6 0.10 mM and, therefore, the
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largest decrease in serum phosphate occurred during the
first 90 minutes of hemodialysis. During the rest of the
session the serum phosphate remained within normal lev-
els. By contrast, during the high-P hemodialysis the serum
phosphate concentration did not change significantly; the
values were 2.21 6 0.21 mM and 2.17 6 0.18 mM before and
after 240 minutes, respectively. During the last additional
hour in which a P-free dialysate was used, the serum
phosphate decreased to a normal level of 1.14 6 0.22 mM
(P , 0.001 vs. 240 min).
The parameters of the PTH-calcium curve obtained with
both the high-P and the P-free hemodialysis are presented
in Table 2. While the basal and maximal PTH were similar,
the minimal PTH was greater during the high-P hemodial-
ysis than the regular P-free hemodialysis 413 6 79 versus
318 6 76 pg/ml, P , 0.003. Since the maximal PTH was
similar during both procedures, the minimal/maximal PTH
ratio was greater during the high-P than P-free hemodial-
ysis. The calcium concentration required to produce the
minimal PTH (Camax) was similar with high P and P-free
hemodialysis. The basal calcium, set point and Camin were
also similar during both procedures. The rate of decline in
serum ionized calcium was similar in both high-P and
P-free hemodialysis; however, the Camax was reached after
51 6 15 minutes in high-P hemodialysis and after 56 6 16
minutes in the P-free hemodialysis. The rate of increase in
serum ionized calcium was greater during the P-free rather
than high-P hemodialysis. Thus, the Camin was reached
after 81 6 24 and 102 6 26 minutes (P 5 0.08) of P-free
and high-P hemodialysis, respectively. According to previ-
ous experiments by others, this difference in the rate
ionized calcium increased does not affect the PTH re-
sponse in humans [19].
The PTH-calcium curves during high-P and P-free he-
modialysis are shown in Figure 2. When the serum ionized
calcium concentration was greater than 1.15 mM, the inhi-
bition of PTH secretion was less during the high-P than the
P-free hemodialysis. The individual values of minimal PTH
during the high-P and the P-free hemodialysis are shown in
Figure 3. Although the interindividual variation was con-
siderable, in all cases the high-P hemodialysis produced an
increase in the minimal PTH. The percent increase in the
minimal PTH post-high-P hemodialysis relative to the













MG F 67 82 Renal Tumor 478 2.6 2.8 4.1 21.5
MMV F 37 5 GN 762 2.4 1.5 4.4 20.1
BM F 73 48 Vasculitis 712 2.4 2.0 4.5 20.5
EP M 70 28 Vasculitis 380 2.2 2.3 4.2 21.2
ESM F 69 108 GN 972 2.6 1.8 4.1 20.3
AZ M 60 10 Nephroagioesclerosis 330 2.1 2.5 3.8 20.7
CQ F 50 72 GN 780 2.5 2.6 4.0 19.8
FP F 81 120 Unknown 1084 2.4 2.3 4.0 26.3
FM M 55 21 GN 636 2.5 2.4 4.1 23.4
RC F 65 32 Polycystic 314 2.5 2.2 4.2 22.1
Abbreviations are: ESRD, end-stage renal disease; i-PTH, intact parathyroid hormone; GN, glomerulonephritis; Ca, calcium; P, phosphate; Alb,
albumin.
Fig. 1. Changes in serum phosphate concentration during the high
phosphate hemodialysis (high-P hemodialysis; F) and the phosphate-free
hemodialysis (P-free hemodialysis; E). Values are the mean 6 SE, N 5 10.
*P , 0.05 versus P-free hemodialysis.
Table 2. Parameters of the PTH-calcium curve
High-P P-free P
Basal PTH pg/ml 617 6 89 631 6 86 NS
Maximal PTH pg/ml 1037 6 166 991 6 146 NS
Minimal PTH pg/ml 413 6 79 318 6 76 0.003
PTHbasal/max % 65 6 5 66 6 4 NS
PTHmin/max % 38 6 4 30 6 5 0.03
Set point mM 1.19 6 0.03 1.17 6 0.03 NS
Basal Ca mM 1.17 6 0.04 1.15 6 0.05 NS
Max Ca mM 1.06 6 0.03 1.03 6 0.04 NS
Min Ca mM 1.24 6 0.03 1.25 6 0.03 NS
Data are mean 6 SE; (N 5 8).
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minimal PTH post P-free hemodialysis was significantly
correlated with the difference between serum phosphate
post-high-P hemodialysis and post-P-free hemodialysis (r 5
0.666, P 5 0.035). None of the parameters of the PTH
calcium curve showed a significant correlation with the
percent increase in minimal PTH after the high-P hemodi-
alysis.
Serum magnesium decreased during both high-P and
P-free hemodialysis, and the change was similar, from
2.35 6 0.16 mg/dl to 1.95 6 0.14 mg/dl (P 5 0.06) and from
2.52 6 0.23 to 2.07 6 0.11 (P 5 0.054), respectively. During
both the high-P and the P-free hemodialysis no statistical
differences were observed at any of the sampling times.
DISCUSSION
The aim of the present study was to evaluate the effects
of a high phosphate concentration on PTH secretion in
hemodialysis patients. The results show that during hemo-
dialysis, the maintenance of high serum phosphate levels by
the addition of phosphate to the dialysate partially pre-
vented the inhibition of PTH secretion by calcium. Thus,
high serum phosphate was associated with an increase in
the minimal PTH.
During regular hemodialysis, the high serum phosphate
concentration decreases to normal levels as phosphate
diffuses across the dialyzer; in our patients, the addition of
phosphate to the dialysate prevented the decrease in serum
phosphate. Thus, this experimental design appears to be
valid to evaluate the effect of high versus normal serum
phosphate concentration on PTH secretion. However, high
extracellular phosphate concentration lowers the serum
calcium concentration acutely; this is due to the fact that
high phosphate decreases the efflux of calcium from bone
[3, 21] and it may also induce precipitation of calcium in
soft tissue [22]. Since low serum calcium is the main
stimulus for PTH secretion, a direct effect of phosphate on
PTH secretion cannot be demonstrated if the change in
serum phosphate produces a concomitant change in serum
calcium. In the present study, we overcame this potential
methodological problem since each patient underwent a
low and high calcium hemodialysis to produce progressive
hypo and hypercalcemia respectively and this was repeated
during both high-P and P-free hemodialysis. Therefore, the
PTH secretion was evaluated at various levels of serum
Fig. 2. The PTH-calcium curve during the high phosphate hemodialysis
(high-P hemodialysis; F) and the phosphate-free hemodialysis (P-free
hemodialysis; E). The PTH values at each calcium concentration are the
means obtained from the individual PTH-calcium curves obtained in the
eight patients studied. *P , 0.05 versus P-free HD. The mean 6 SE PTH
value at 1.15 mM calcium is 767 6 131 and 554 6 115 pg/ml for high-P and
P-free hemodialysis, respectively (P , 0.05). Note that these values are not
identical to the mean basal PTH values presented in Table 2. In Table 2
the mean basal PTH value was obtained from basal PTH values corre-
sponding to each individual basal calcium, which varies from patient to
patient. The change from each individual basal calcium concentration to a
calcium of 1.15 induces a change in PTH. This explains that the mean PTH
at 1.15 mM calcium is not the same as the mean basal PTH presented in
Table 2. Fig. 3. Individual values of maximal inhibition of PTH secretion (mini-
mal PTH) with hypercalcemia during the high phosphate hemodialysis
(high-P hemodialysis) and the phosphate-free hemodialysis (P-free he-
modialysis). Dashed circles indicates that P-free hemodialysis was per-
formed first. In all patients the values of minimal PTH were greater during
the high-P hemodialysis than the P-free hemodialysis.
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calcium concentration in the presence of high and normal
serum phosphate.
Our data showed that the degree of calcium induced
PTH suppression was less during high-P than P-free hemo-
dialysis. This relatively high PTH level despite hypercalce-
mia was attributed to the hyperphosphatemia. The fact that
the increase in minimal PTH after high-P hemodialysis is
proportional to the increase in phosphate contributes to
demonstrate that the high phosphate is directly responsible
for the increase in minimal PTH. It is known that the
PLA2-arachidonic acid signaling pathway is involved in the
inhibition of PTH secretion by high calcium [23]. We have
shown that high phosphate inhibits arachidonic acid pro-
duction [24]. These findings suggest that high phosphate
affects PTH secretion in a situation of hypercalcemia.
Another potential variable that could have influenced
PTH secretion was the decrease in serum magnesium
concentration [25] usually observed during hemodialysis
[26]. However, in our patients the decrease in magnesium
was similar during the high-P and P-free hemodialysis.
Thus, the high PTH levels during high-P hemodialysis were
not due to differences in magnesium concentration.
Recent work has demonstrated a direct effect of phos-
phate on PTH secretion [14–16], gene expression [6, 27, 28]
and parathyroid cell proliferation [15, 29–32]. A direct
effect of extracellular phosphate in the regulation of para-
thyroid cell function seems reasonable based on these
experimental studies; however, a direct effect of phosphate
on PTH secretion in hemodialysis patients has not been
previously reported. Although the long-term increase in
serum phosphate increases PTH levels in only 50% of the
patients [33], it is known that in predialysis patients a
decrease in serum phosphate is followed by a reduction in
PTH levels [34]. Furthermore, in hemodialysis patients with
secondary hyperparathyroidism and hyperphosphatemia,
the PTH levels fail to decrease in response to calcitriol
therapy [13, 35]. This lack of response may be explained by
the stimulatory effect of high phosphate on parathyroid
cells.
In conclusion, during hemodialysis, the high serum phos-
phate level prevented the inhibition of PTH secretion by
calcium, which strongly suggests that in dialysis patients the
high serum phosphate contributes directly to the elevation
of PTH levels despite normal or high serum calcium
concentration.
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